Добавил:
Sekretar
kiopkiopkiop18@yandex.ru
t.me/Prokururor I Вовсе не секретарь, но почту проверяю
Опубликованный материал нарушает ваши авторские права? Сообщите нам.
Вуз:
Предмет:
Файл:Ординатура / Хирургия / Библиотека им академика М.И. Перельмана / Книга_5444_Библиотеки_им_академика_М_И_Перельмана
.pdf
11 Nanodelivery of Polyphenols as Nutraceuticals for CNS Disorders
238
11.4.3.4 Ethosomes
Ethosomes are phospholipid vesicles comprising a drug molecule in the inner core and ethanol at
a higher concentration. Because of these features, ethanol can solubilize with a variety of bioac-
tives and improve the penetration profile through the skin [127–129]. Kayal et al. (2019) and Faisal
et al. (2016) prepared EGCG-loaded ethosomes for effective delivery and better therapeutic anti-
oxidant potential and photostability [130, 131].
11.4.3.5 Nutraceuticals as a Source for Polyphenols
Nutraceuticals are an organic compound comprising various polyphenols obtained from plants
and they have wide application in the treatment of various human disorders (Figure 11.4). These
are basically used for health benefits, prevention, and treatment of various medical conditions
with no side effects. These nutraceutical products are currently available in the global market with
different brand names. Some of these patents are listed in Table 11.2. Marketed products are listed
in Table 11.3. Overall, these nutraceuticals are a multibillion-dollar industry [141].
Table 11.2 Patents of polyphenolic drug delivery for central nervous system disorders.
Patent No. Polyphenol Used Formulation Diseases References
WO2008/005577 Epigallocatechin-3-gallate,
epicatechin (Green tea polyphenols)
– Dementia [139]
CN111803632A Flavone polyphenol Phospholipid
complex
– [140]
Management
of blood
glucose
Management
of central
nervous
system
IRON
SUPPLYMENT
Antioxidant
supplements
Vitamins Cholesterol
management
Bone
strengthening
SCOPE OF
NUTRACEUTICALS
Figure 11.4 Scope of nutraceuticals.
https://t.me/medicina_free
References 239
11.5 Conclusion and Future Perspectives
Polyphenols are nutraceuticals that have a wide scope in the treatment of various CNS disorders,
including Alzheimer’, Parkinson’s, migraines, and other medical conditions. The main challenge
of polyphenols is their poor aqueous solubility, which causes low bioavailability and stability.
Therefore, in recent years, various nanocarriers have been investigated for the delivery of polyphe-
nols, including nanoparticles, SLNs, nanostructured lipid carriers, metallic nanoparticles, vesicu-
lar carriers, liposomes, niosomes, and micelles. These nanoengineered carriers introduce new
avenues over the conventional formulations for improving stability and bioavailability. These
agents are promising for the nanodelivery of polyphenols because of their unique profiles. In addi-
tion, formulation development and commercialization of these nanocarriers for polyphenols as
nutraceuticals must be performed.
Acknowledgment
The authors are thankful to the Librarian of the Central Library and the Director of Shri Govindram
Seksaria Institute of Technology and Science (SGSITS), Indore for providing necessary e-resources,
Inflibnet and lab facilities.
References
1 Davis, M.E. (2018). Epidemiology and overview of gliomas. Seminars in Oncology Nursing 34 (5):
420–429.
2 Ostrom, Q.T., Gittleman, H., Liao, P. et al. (2021). CBTRUS Statistical report: primary brain and
other central nervous system tumors diagnosed in the United States in 2010–2014. Neuro-Oncology
19 (suppl_5): v1–v88.
Table 11.3 Marketed polyphenols used as nutraceuticals.
Brand Name Manufacturer Available Dose Benefits
Magnum Big C
TM
Magnum
®
Nutraceuticals
Capsule Muscle gainer, water balance
Iron Folic Nutrilite
®
Tablet Iron supplements, anemia
Acai berry pure Natures Craft
®
Capsule Vitamins, minerals, antioxidant
supplements
Nutrela
TM
Omega Patanjali
®
Ayurved Capsule Improve heart, skin, eye, brain
function, and cholesterol management
Nutrela
TM
Bone
health
Patanjali
®
Ayurved Capsule Improve bone, fracture healing, and
bone strengthening
Nutrela
TM
Diabetic Care
Patanjali
®
Ayurved Powder Management of blood glucose and
weight
BeneFlora
®
S Probiotic
Shreya Life science Capsule Pro- and pre-biotic supplement
https://t.me/medicina_free
11 Nanodelivery of Polyphenols as Nutraceuticals for CNS Disorders
240
3 Louis, D.N., Perry, A., Wesseling, P. et al. (2021). The 2021 WHO classification of tumors of the
central nervous system: a summary. Neuro-oncology 23 (8): 1231–1251.
4
Wen, P.Y. and Brandes, A.A. (2009). Treatment of recurrent high-grade gliomas. Current Opinion
in Neurology 22 (6): 657–664.
5
Xiong, L., Wang, F., and Qi, X.X. (2019). Advanced treatment in high-grade gliomas. Journal of
BUON: Official Journal of the Balkan Union of Oncology 24 (2): 424–430.
6
Gauthier, S., Rosa-Neto, P., Morais, J.A., and Webster, C. (2021). World Alzheimer Report 2021:
Journey Through the Diagnosis of Dementia. London, England: Alzheimer’s Disease International.
7
Cahill, S. (2020 Feb). WHO’s global action plan on the public health response to dementia: some
challenges and opportunities. Aging and Mental Health 24 (2): 197–199. https://doi.org/10.1080/13
607863.2018.1544213. Epub 2019 Jan 2. PMID: 30600688.
8
Kuang, J., Zhang, P., Cai, T. et al. (2021). Prediction of transition from mild cognitive impairment
to Alzheimer’s disease based on a logistic regression–artificial neural network–decision tree
model. Geriatrics & Gerontology International 21 (1): 43–47.
9
Pagani, M., Giuliani, A., Öberg, J. et al. (2016). Predicting the transition from normal aging to
Alzheimer’s disease: a statistical mechanistic evaluation of FDG-PET data. Neuroimage 141:
282–290.
10
Thawkar, B.S. and Kaur, G. (2019). Inhibitors of NF-κB and P2×7/NLRP3/Caspase 1 pathway in
microglia: novel therapeutic opportunities in neuroinflammation induced early-stage Alzheimer’s
disease. Journal of Neuroimmunology 326: 62–74.
11
Abdivalievna, A.N. (2022). Features of cognitive disorders. Innovative Society: Problems, Analysis
and Development Prospects 101–105.
12
Pandey, P. and Sharma, P. (2011). Analysis of early onset of Alzheimer’s disease genes: disease
causing and risk factors. European Journal of Biological Research 11 (2): 251–259.
13
Schneider, L.S., Mangialasche, F., Andreasen, N. et al. (2014). Clinical trials and late‐stage drug
development for Alzheimer’s disease: an appraisal from 1984 to 2014. Journal of Internal Medicine
275 (3): 251–283.
14
Valkova, P. and Pohanka, M. (2021). Novel trends in electrochemical biosensors for early diagnosis
of Alzheimer’s disease. International Journal of Analytical Chemistry 2021: 1–13.
15
Passeri, E., Elkhoury, K., Morsink, M. et al. (2022). Alzheimer’s disease: treatment strategies and
their limitations. International Journal of Molecular Sciences 23 (22): 120–139.
16
Tysnes, O.-B. and Storstein, A. (2017). Epidemiology of Parkinson’s disease. Journal of Neural
Transmission 124 (8): 901–905.
17 Jankovic, J. and Tan, E.K. (2020). Parkinson’s disease: etiopathogenesis and treatment. Journal of
Neurology, Neurosurgery, and Psychiatry 91 (8): 795–808.
18 Elsworth, J.D. (2020). Parkinson’s disease treatment: past, present, and future. Journal of Neural
Transmission (Vienna, Austria: 1996) 127 (5): 785–791.
19 Lang, A.E. and Espay, A.J. (2018). Disease modification in Parkinson’s disease: current
approaches, challenges, and future considerations. Movement Disorders Official Journal of the
Movement Disorder Society 33 (5): 660–677.
20
Hulisz, D. (2018). Amyotrophic lateral sclerosis: disease state overview. The American Journal of
Managed Care 24 (15 Suppl): S320–S326.
21 Oskarsson, B., Gendron, T.F., and Staff, N.P. (2018). Amyotrophic lateral sclerosis: an update for
2018. Mayo Clinic Proceedings 93 (11): 1617–1628.
22 Al-Chalabi, A., Jones, A., Troakes, C. et al. (2012). The genetics and neuropathology of
amyotrophic lateral sclerosis. Acta Neuropathologica 124 (3): 339–352.
23 Brown, R.H. and Al-Chalabi, A. (2017). Amyotrophic lateral sclerosis. New England Journal of
Medicine 377 (2): 162–172.
https://t.me/medicina_free
References 241
24 Stoker, T.B., Mason, S.L., Greenland, J.C. et al. (2022). Huntington’s disease: diagnosis and
management. Practical Neurology 22 (1): 32–41.
25
Pandey, M. and Rajamma, U. (2018). Huntington’s disease: the coming of age. Journal of Genetics
97 (3): 649–664.
26
Johnson, E.B. and Gregory, S. (2019). Huntington’s disease: brain imaging in Huntington’s
disease. Progress in Molecular Biology and Translational Science 165: 321–369.
27
Hui, C., Tadi, P., and Patti, L. (2022). Ischemic Stroke. StatPearls. Treasure Island (FL): StatPearls
Publishing. Copyright ©, StatPearls Publishing LLC.
28
Unnithan, A.K.A., J, M.D., and Mehta, P. (2022). Hemorrhagic Stroke. StatPearls. Treasure Island
(FL): StatPearls Publishing. Copyright ©, StatPearls Publishing LLC.
29
Verma, N. (2016). Review on phytoconstituents and their mode of extractions: an overview.
Research Journal of Chemical and Environmental Sciences 4 (2): 8–15.
30
Densie, W. (2013). Phytochemicals role in good health. The Magazine for Nutrition Professionals
15: 1–10.
31
Archivio, D., Filesi, M., Di Benedetto, C. et al. (2007). Polyphenols, dietary sources and
bioavailability. Annali-IstitutoSuperiore Di Sanita 43: 348.
32
Scalbert, A., Johnson, I.T., and Saltmarsh, M. (2005). Polyphenols: antioxidants and Beyond. The
American Journal of Clinical Nutrition 81: 215S–217S.
33
Marrugat, J., Covas, M.I., Fitó, M. et al. (2004). Effects of differing phenolic content in dietary olive
oils on lipids and LDL oxidation. European Journal of Nutrition 43: 140–147.
34
Behl, T., Bungau, S., Kumar, K. et al. (2020). Pleotropic effects of polyphenols in cardiovascular
system. Biomedicine & Pharmacotherapy 130: 110714.
35
Rasouli, H., Farzaei, M.H., and Khodarahmi, R. (2017). Polyphenols and their benefits: a review.
International Journal of Food Properties 20 (2): 1700–1741.
36
Shahidi, F. and Yeo, J. (2018). Bioactivities of phenolics by focusing on suppression of chronic
diseases: a review. International Journal of Molecular Sciences 19 (6): 1573.
37
Rashmi, H.B. and Negi, P.S. (2020). Phenolic acids from vegetables: a review on processing
stability and health benefits. Food Research International 10: 92–98.
38
Ozcan, T., Akpinar-Bayizit, A., Yilmaz-Ersan, L., and Delikanli, B. (2014). Phenolics in human
health. International Journal of Chemical Engineering and Applications 5 (5): 393.
39
Gupta, S., Bishnoi, J.P., Kumar, N. et al. (2018). Terminalia arjuna (Roxb.) Wight &Arn.:
competent source of bioactive components in functional food and drugs. The Pharma Innovation
Journal 7 (3): 223–231.
40 Singla, R.K., Dubey, A.K., Garg, A. et al. (2019). Natural Polyphenols: Chemical Classification,
Definition of Classes, Subcategories, and Structures. Oxford University Press.
41 Teixeira, J., Gaspar, A., Garrido, E.M. et al. (2013). Hydroxycinnamic acid antioxidants: an
electrochemical overview. BioMed Research International 4: 112–136.
42 Baniwal, P., Mehra, R., Kumar, N. et al. (2021). Cereals: functional constituents and its health
benefits. Pharma Innovation 10 (3): 01–7.
43 Yadav, D., Kumar, H., Kumar, A. et al. (2016). Optimization of polyphenolic fortification of grape
peel extract in stirred yogurt by response surface methodology. Indian Journal of Dairy Science 69
(1): 124–144.
44 Harborne, J.B. (ed.) (2013). The Flavonoids: Advances in Research Since 1980. 621. New York, NY:
Springer. https://doi.org/10.1007/978-1-4899-2913-6.
45 Ballard, C.R. and Junior, M.R.M. (2019). Health benefits of flavonoids. In: Bioactive Compounds,
185–201. Elsevier. https://doi.org/10.1016/b978-0-12-814774-0.00010-4.
46 Sandu, M., Bîrsă, L.M., and Bahrin, L.G. (2017). Flavonoids–small molecules, high hopes. Acta
Chemica Iasi 25 (1): 6–23.
https://t.me/medicina_free
11 Nanodelivery of Polyphenols as Nutraceuticals for CNS Disorders
242
47 Nikolić, I.L., Savić-Gajić, I.M., Tačić, A.D., and Savić, I.M. (2017). Classification and biological
activity of phytoestrogens: a review. Advanced Technologies 6 (2): 96–106.
48
Zaheer, K. and Humayoun, A.M. (2017). An updated review of dietary isoflavones: nutrition,
processing, bioavailability and impacts on human health. Critical Reviews in Food Science and
Nutrition 57 (6): 1280–1293.
49
Calderón-Oliver, M. and Ponce-Alquicira, E. (2018). Fruits: a source of polyphenols and health
benefits. In: Natural and Artificial Flavouring Agents and Food Dyes (ed. A.M. Grumezescu and
A.M. Holban), 189–228. Academic Press, Elsevier. https://doi.org/10.1016/
B978-0-12-811518-3.00007-7.
50
Wrolstad, R.E. (2004). Anthocyanin pigments—bioactivity and coloring properties. Journal of
Food Science 69 (5): C419–C425.
51
Welch, C.R., Wu, Q., and Simon, J.E. (2008). Recent advances in anthocyanin analysis and
characterization. Current Analytical Chemistry 4 (2): 75–101.
52
Krga, I. and Milenkovic, D. (2029). Anthocyanins: from sources and bioavailability to
cardiovascular-health benefits and molecular mechanisms of action. Journal of Agricultural and
Food Chemistry 67 (7): 1771–1783.
53
Cutrim, C.S. and Cortez, M.A.S. (2018). A review on polyphenols: classification, beneficial effects
and their application in dairy products. International Journal of Dairy Technology 71 (3): 564–578.
54
Kumar, H., Choudhary, N., Varsha, K.N., and Suman, S.R. (2014). Phenolic compounds and their
health benefits: a review. Journal of Food Technology Research 2: 46–59.
55
Popa, V.I., Dumitru, M., Volf, I., and Anghel, N. (2008). Lignin and polyphenols as allelochemicals.
Industrial Crops and Products 27 (2): 144–149.
56
Radko, L. and Cybulski, W. (2007). Application of silymarin in human and animal medicine.
Journal of Pre-Clinical and Clinical Research 1 (1): 125–146.
57
Shen, T., Wang, X.N., and Lou, H.X. (2009). Natural stilbenes: an overview. Natural Product
Reports 26 (7): 916–935.
58
Chou, Y.C., Ho, C.T., and Pan, M.H. (2018). Stilbenes: chemistry and molecular mechanisms of
anti-obesity. Current Pharmacology Reports 4 (3): 202–209.
59
Baur, J.A. and Sinclair, D.A. (2006). Therapeutic potential of resveratrol: the in vivo evidence.
Nature Reviews Drug Discovery 5 (6): 493–506.
60
Nandagopal, A. and Siddiqui, K. (2019). Role of nutraceuticals in neurodegenerative diseases. Acta
PharmaceuticaSuecica 57 (4): 117–131.
61 Defelice, S.L. (1995). The nutraceutical revolution – its impact on food industry R&D. Trends in
Food Science and Technology 6: 59–61.
62 Feng, Y., Wang, X.P., Yang, S.G. et al. (2009). Resveratrol inhibits betaamyloid oligomeric
cytotoxicity but does not prevent oligomer formation. NeuroToxicology 30 (6): 986–995.
63 Huang, T.C., Lu, K.T., Wo, Y.Y. et al. (2011). Resveratrol protects rats from A
β
induced neurotoxicity
by the reduction of iNOS expression and lipid peroxidation. PLoS ONE 6 (12): Article IDe29102.
64 Frozza, R.L., Bernardi, A., Paese, K. et al. (2010). Characterization of trans-resveratrol-loaded
lipid-core nanocapsules and tissue distribution studies in rats. Journal of Biomedical
Nanotechnology 6 (6): 694–703.
65 Ushikubo, H., Watanabe, S., Tanimoto, Y. et al. (2012). 3, 3ʹ, 4ʹ, 5, 5ʹ Pentahyroxyflavone is a
potent inhibitor of amyloid
β
fibril formation. Neuroscience Letters 513 (1): 51–56.
66 Gong, E.J., Park, H.R., Kim, M.E. et al. (2011). Morin attenuates tau hyperphosphorylation by
inhibiting GSK3
β
. Neurobiology of Disease 44 (2): 223–230.
https://t.me/medicina_free
References 243
67 Devi, L. and Ohno, M. (2012). 7, 8-dihyroxyflavone, a small molecule TrkB agonist, reverses
memory deficits and BACE1 elevation in amouse model of Alzheimer’s disease.
Neuropsychopharmacology 37 (2): 434–444.
68
Wang, J., Pfleger, C.M., Friedman, L. et al. (2010). Potential application of grape derived
polyphenols in huntington’s disease. Translational Neuroscience 1 (2): 95–100.
69
Sternberg, Z., Chadha, K., Lieberman, A. et al. (2008). Quercetin and interferon-β modulate
immune response(s) in peripheral blood mononuclear cells isolated from multiple sclerosis
patients. Journal of Neuroimmunology 205: 142–147.
70
Herges, K., Millward, J.M., Hentschel, N. et al. (2016). Neuroprotective effect of combination
therapy of glatiramer acetate and epigallocatechin-3-gallate in neuroinflammation. PLoS ONE 6
(10): Article ID e25456.
71
Davis, J.M., Murphy, E.A., Carmichael, M.D., and Davis, B. (2009). Quercetin increases brain and
muscle mitochondrial biogenesis and exercise tolerance. American Journal of Physiology 296 (4):
1071–1077.
72
Xiang, L., Sun, K., Lu, J. et al. (2011). Anti-aging effects of phloridzin, an apple polyphenol, on
yeast via the SOD and Sir2 genes. Bioscience, Biotechnology and Biochemistry 75 (5): 854–858.
73
Hong, K.S., Park, J.I., Kim, M.J. et al. (2012). Involvement of SIRT1 in hypoxic down-regulation of
c-Myc and β-catechin and hypoxic precondition effect of polyphenol. Toxicology and Applied
Pharmacology 259 (2): 210–218.
74
Park, J.W., Hong, J.S., Lee, K.S. et al. (2010). Green tea polyphenol (-)-epigallocatechin gallate
reduces matrix metalloproteinase-9 activity following transient focal cerebral ischemia. Journal of
Nutritional Biochemistry 21 (11): 1038–1044.
75
Panickar, K.S., Polansky, M.M., and Anderson, R.A. (2009). Green tea polyphenols attenuate glial
swelling and mitochondrial dysfunction following oxygen-glucose deprivation in cultures.
Nutritional Neuroscience 12 (3): 105–113.
76
Khan, M.M., Ahmad, A., Ishrat, T. et al. (2009). Rutin protects the neural damage induced by
transient focal ischemia in rats. Brain Research 1292: 123–135.
77
Gelderblom, M., Leypoldt, F., Lewerenz, J. et al. (2012). The flavonoid fisetin attenuates
postischemic immune cell infiltration, activation and infract size after transient cerebral middle
artery occlusion in mice. Journal of Cerebral Flow and Blood Metabolism 32 (5): 835–843.
78
Tu, X.K., Yang, W.Z., Liang, R.S. et al. (2011). Effect of baicalin on matrix metalloproteinase-9
expression and blood brain barrier permeability following focal cerebral ischemia in rats.
Neurochemical Research 36 (11): 2022–2028.
79 Cao, Y., Mao, X., Sun, C. et al. (2011). Baicalin attenuates global cerebral ischemia/reperfusion
injury in gerbils via anti-oxidative and anti-apoptotic pathways. Brain Research Bulletin 85 (6):
396–402.
80
Cui, L., Zhang, X., Yang, R. et al. (2010). Baicalein is neuroprotective in ratMCAOmodel: role of
12/15-lipoxygenase, mitogen-activated protein kinase and cytosolic phospholipase A2.
Pharmacology Biochemistry and Behavior 96 (4): 469–475.
81 Tu, X.K., Yang, W.Z., Shi, S.S. et al. (2011). Baicalin inhibits TLR2/4 signaling pathway in rat brain
following permanent cerebral ischemia. Inflammation 34 (5): 463–470.
82 Ho, D.J., Calingasan, N.Y., Wille, E. et al. (2010). Resveratrol protects against peripheral deficits in
amouse model of Huntington’s disease. Experimental Neurology 225: 74–84.
83 Jin, F., Wu, Q., Lu, Y.F. et al. (2008). Neuroprotective effect of resveratrol on 6–OHDA-induced
Parkinson’s disease in rats. European Journal of Pharmacology 600: 78–82.
https://t.me/medicina_free
11 Nanodelivery of Polyphenols as Nutraceuticals for CNS Disorders
244
84 Khan, M.M., Ahmad, A., Ishrat, T. et al. (2010). Resveratrol attenuates 6-hydroxydopamine-
induced oxidative damage and dopamine depletion in rat model of Parkinson’s disease. Brain
Research 1328: 139–151.
85
Filomeni, G., Graziani, I., Zio, D.D. et al. (2010). Neuroprotection of kaempferol by autophagy in
models of rotenone-mediated acute toxicity: possible implications for Parkinson’s disease.
Neurobiology of Aging 24: 85–91.
86
Vauzour, D., Corona, G., and Spencer, J.P.E. (2018). Caffeic acid, tyrosol and p-coumaric acid are
potent inhibitors of 5-S-cysteinyldopamine induced neurotoxicity. Archives of Biochemistry and
Biophysics 501: 106–111.
87 Tai, K.K. and Truong, D.D. (2010). (-)-Epigallocatechin-3-gallate (EGCG), a green tea polyphenol,
reduces dichlorodiphenyltrichloroethane (DDT)-induced cell death in dopaminergic SHSY-5Y
cells. Neuroscience Letters 482 (3): 183–187.
88
Kim, H.G., Ju, M.S., Shim, J.S. et al. (2010). Mulberry fruit protects dopaminergic neurons in
toxin-induced Parkinson’s disease models. The British Journal of Nutrition 104: 8–16.
89
Maher, P., Dargusch, R., Bodai, L. et al. (2011). Erk activation by the polyphenols fisetin and
resveratrol provides neuroprotection in multiple models of Huntington’s disease.
HumanMolecular Genetics 20: 261–270.
90
Kumar, P. and Kumar, A. (2010). Protective effect of hesperidin and naringin against
3-nitropropionic acid induced Huntington’s like symptoms in rats: possible role of nitric oxide.
Behavioural Brain Research 206: 38–46.
91
Hickey, M.A., Zhu, C., Medvedeva, V. et al. (2003). Improvement of neuropathology and
transcriptional deficits in CAG 140 knockin mice supports a beneficial effect of dietary curcumin
in Huntington’s disease. Molecular Neurodegeneration 4: 7–12.
92
Ehrnhoefer, D.E., Duennwald, M., Markovic, P. et al. (2006). Mitochondrial dysfunction and tau
hyperphosphorylation in Ts1Cje, a mouse model for down syndrome. Human Molecular Genetics
18: 2752–2762.
93 Duraˇckov´a, Z. (2010). Some current insights into oxidative stress. Physiological Research 59:
459–469.
94
Sanmukhani, V., Satodia, J., Trivedi, J. et al. (2014). Efficacy and safety of curcumin in major
depressive disorder: a randomized controlled trial. Phytotherapy Research 28 (4): 579–585.
95
Chen, W.Q., Zhao, X.L., Hou, Y. et al. (2009). Protective effects of green tea polyphenols on
cognitive impairments induced by psychological stress in rats. Behavioural Brain Research 202:
71–76.
96 Zhu, W.L., Shi, H.S., Wei, Y.M. et al. (2012). Green tea polyphenols produce antidepressant-like
effects in adult mice. Pharmacological Research 65: 74–80.
97 Vignes, M., Maurice, T., Lant´e, F. et al. (2006). Anxiolytic properties of green tea polyphenol
(-)-epigallocatechin gallate (EGCG). Brain Research 1110: 102–115.
98 Zhang, Q., Yang, H., Wang, J. et al. (2013). Effect of green tea on reward learning in healthy
individuals: a randomized, double-blind, placebo-controlled pilot study. Nutrition Journal 12: 1–7.
99 Hou, Y., Aboukhatwa, M.A., Lei, D.L. et al. (2010). Anti-depressant natural flavonols modulate
BDNF and beta amyloid in neurons and hippocampus of double TgAD mice. Neuropharmacology
58: 911–920.
100 Dreiseitel, G., Korte, P., Schreier, P. et al. (2009). Berry anthocyanins and their aglycons inhibit
monoamine oxidases A and B. Pharmacological Research 59: 306–311.
101 Messaoudi, M., Bisson, J.F., Nejdi, A. et al. (2008). Antidepressant-like effects of a cocoa
polyphenolic extract in Wistar-Unilever rats. Nutritional Neuroscience 11: 269–276.
https://t.me/medicina_free
References 245
102 Sathyapalan, T., Beckett, S., Rigby, A.S. et al. (2010). High cocoa polyphenol rich chocolate may
reduce the burden of the symptoms in chronic fatigue syndrome. Nutrition Journal 9 (55): 87–95.
103
Coghill, D., Bonnar, S., Duke, S. et al. (2009). Child and Adolescent Psychiatry. New York, NY,
USA: Oxford University Press.
104
Yoon, S.Y., Pe˜na, I.D., Kim, S.M. et al. (2013). Oroxylin A improves attention deficit hyperactivity
disorder-like behaviors in the spontaneously hypertensive rat and inhibits reuptake of dopamine
in vitro. Archives of Pharmacal Research 36: 134–140.
105
Loftis, J.M., Wilhelm, C.J., and Huckans, M. (2013). Effect of epigallocatechin gallate
supplementation in schizophrenia and bipolar disorder: an 8-week, randomized, double-blind,
placebo controlled study. Therapeutic Advances in Psychopharmacology 3: 21–27.
106
Dietrich-Muszalska, K.B., Olas, B., and Rabe- Jablo´nska, J. (2012). Epicatechin inhibits human
plasma lipid peroxidation caused by haloperidol in vitro. Neurochemical Research 37: 557–562.
107
Dietrich-Muszalska, A., Kopka, J., and Kontek, B. (2014). Polyphenols from berries of Aronia
melanocarpa reduce the plasma lipid peroxidation induced by Ziprasidone. Schizophrenia
Research and Treatment 7: 45–52.
108
Zhang, W.F., Tan, Y.L., Zhang, X.Y. et al. (2011). Extract of Ginkgo biloba treatment for tardive
dyskinesia in schizophrenia: a randomized, doubleblind, placebo-controlled trial. Journal of
Clinical Psychiatry 72: 615–621.
109
Suresh, P. and Raju, A.B. (2013). Antidopaminergic effects of leucine and genistein on
shizophrenic rat models. Neurosciences 18: 235–241.
110
Li, H., Yan, Z., Zhu, J. et al. (2011). Neuroprotective effects of resveratrol on ischemic injury
mediated by improving brain energy metabolism and alleviating oxidative stress in rats.
Neuropharmacology 60: 252–258.
111
Li, C., Yan, Z., Yang, J. et al. (2010). Neuroprotective effects of resveratrol on ischemic injury
mediated by modulating the release of neurotransmitter and neuromodulator in rats.
Neurochemistry International 56: 495–500.
112 Yang, X., Li, Z., Wang, N. et al. (2015). Curcumin-encapsulated polymeric micelles suppress the
development of colon cancer in vitro and in vivo. Scientific Reports 18; 5 (1): 1–5.
113
Aguilar, Z.P. (2013). Types of nanomaterials and corresponding methods of synthesis.
Nanomaterials for Medical Applications 50: 15–29.
114
Yang, B., Dong, Y., Wang, F., and Zhang, Y. (2020). Nanoformulations to enhance the
bioavailability and physiological functions of polyphenols. Molecules 25 (20): 4613.
115 Mohanty, C., Acharya, S., Mohanty, A.K. et al. (2010). Curcumin-encapsulated MePEG/PCL
diblock copolymeric micelles: a novel controlled delivery vehicle for cancer therapy.
Nanomedicine 5 (3): 433–449.
116 Khonkarn, R., Mankhetkorn, S., Hennink, W.E., and Okonogi, S. (2011). PEG-OCL micelles for
quercetin solubilization and inhibition of cancer cell growth. European Journal of Pharmaceutics
and Biopharmaceutics 79 (2): 268–275.
117
Šmejkalová, D., Muthný, T., Nešporová, K. et al. (2017). Hyaluronan polymeric micelles for
topical drug delivery. Carbohydrate Polymers 20; 156: 86–96.
118 Lapteva, M., Mondon, K., Möller, M. et al. (2014). Polymeric micelle nanocarriers for the
cutaneous delivery of tacrolimus: a targeted approach for the treatment of psoriasis. Molecular
Pharmaceutics 11 (9): 2989–3001.
119 Chavoshy, F., Zadeh, B.S., Tamaddon, A.M., and Anbardar, M.H. (2020). Delivery and anti-
psoriatic effect of silibinin-loaded polymeric micelles: an experimental study in the psoriatic skin
model. Current Drug Delivery 17 (9): 787–798.
https://t.me/medicina_free
11 Nanodelivery of Polyphenols as Nutraceuticals for CNS Disorders
246
120 Casiraghi, A., Franzè, S., Selmin, F. et al. (2017). Investigation of the effect of different emulsifiers
on the transdermal delivery of EGCG entrapped in a polymeric micelle system. Planta Medica 83
(05): 405–411.
121
Jiang, W., Wang, Q., Cui, D. et al. (2023). Metal-polyphenol network coated magnetic
hydroxyapatite for pH-activated MR imaging and drug delivery. Colloids and Surfaces B:
Biointerfaces 1 (222): 113076.
122
Guo, Y., Sun, Q., Wu, F.G. et al. (2021). Polyphenol‐containing nanoparticles: synthesis,
properties, and therapeutic delivery. Advanced Materials 33 (22): 2007356.
123
Park, S., Cha, S.H., Cho, I. et al. (2016). Antibacterial nanocarriers of resveratrol with gold and
silver nanoparticles. Materials Science and Engineering: C 58: 1160–1169.
124
Qiu, C., McClements, D.J., Jin, Z. et al. (2020). Wang J. Resveratrol-loaded core-shell
nanostructured delivery systems: cyclodextrin-based metal-organic nanocapsules prepared by
ionic gelation. Food Chemistry 317: 126328.
125
Product brochures, indena. Available at http://www.indena.com/pages/brochures.php (Accessed
on 21st April 2011).
126
Pandey, S. and Patel, K. (2010). Phytosomes: technical revolution in phytomedicine. International
Journal of Pharmtech Research 2: 627–631.
127
Rudrapal, M., Mishra, A.K., Rani, L. et al. (2022). Nanodelivery of dietary polyphenols for
therapeutic applications. Molecules 27: 8706. https://doi.org/10.3390/molecules27248706.
128
Verma, P. and Pathak, K. (2010). Therapeutic and cosmeceutical potential of ethosomes: an
overview. Journal of Advanced Pharmacy Technology Research 1: 274–282.
129
Paliwal, S., Tilak, A., Sharma, J. et al. (2019). Flurbiprofen loaded ethosomes transdermal delivery
of anti-inflammatory effect in rat model. Lipids Health Disease 518: 133.
130
Kayal, E.M., Nasr, M., Elkheshen, S., and Mortada, N. (2019). Colloidal (-)-epigallocatechin-3-gallate
vesicular systems for prevention and treatment of skin cancer: a comprehensive experimental study
with preclinical investigation. European Journal of Pharmaceutical Sciences 137: 104972.
131 Faisal, W., Soliman, G.M., and Hamdan, A. (2016). Enhanced skin deposition and delivery of
voriconazole using ethosomal preparations. Journal of Liposome Research 28: 14–21.
132
Palle, S. and Neerati, P. (2018). Improved neuroprotective effect of resveratrol nanoparticles as
evinced by abrogation of rotenone-induced behavioral deficits and oxidative and mitochondrial
dysfunctions in rat model of Parkinson’s disease. Naunyn-Schmiedeberg's Archives of
Pharmacology 391: 445–453. https://doi.org/10.1007/s00210-018-1474-8.
133
Frozza, R.L., Bernardi, A., Paese, K. et al. (2010). Characterization of trans-resveratrol-loaded
lipid-corenanocapsules and tissue distribution studies in rats. Journal of Biomedical
Nanotechnology 6: 694–703. https://doi.org/10.1166/jbn.2010.1161.
134 Frozza, R.L., Bernardi, A., Hoppe, J.B. et al. (2013b). Neuroprotective effects of resveratrol against
Ab administration in rats are improved by lipid-core nanocapsules. Molecular Neurobiology 47:
1066–1080. https://doi.org/10.1007/s12035-013-8401-2.
135
Lu, X., Ji, C., Xu, H. et al. (2009). Resveratrol-loaded polymeric micelles protect cells from
Abeta-induced oxidative stress. International Journal of Pharmaceutics 375: 89–96. https://doi.
org/10.1016/j.ijpharm.2009.03.021.
136 Loureiro, J., Andrade, S., Duarte, A. et al. (2017). Resveratrol and grape extract-loaded solid lipid
nanoparticles for the treatment of Alzheimer’s disease. Molecules 22: E277. https://doi.
org/10.3390/molecules22020277.
137 Wang, Y., Xu, H., Fu, Q. et al. (2011). Protective effect of resveratrol derived from Polygonum
cuspidatum and its liposomal form on nigral cells in parkinsonian rats. Journal of the
Neurological Sciences 304: 29–34. https://doi.org/10.1016/j.jns.2011.02.025.
https://t.me/medicina_free
References 247
138 Da Rocha Lindner, G., Bonfanti, S.D., Colle, D. et al. (2015). Improved neuroprotective effects of
resveratrol-loaded polysorbate 80-coated poly(lactide) nanoparticles in MPTP induced
Parkinsonism. Nanomedicine 10: 1127–1138. https://doi.org/10.2217/nnm.14.165.
139
Shytle, R.D., Bruce, B.D.B., Tampa, F.L. et al. (2008). Composition of polyphenols and methods of
use. WO2008/005577 A3.
140
Beijing, Wehand Bio Pharmaceutical Co ltd, Institute of Materia Medica of CAMS (2019). Flavone
polyphenol medicine self-emulsifying composition, preparation method thereof, medicine
composition and application. Beijing Wehand Bio Pharmaceutical Co ltd Institute of Materia
Medica of CAMS. CN111803632A.
141
Ishak, K.A., Mohamad, A.M.S., and Ahmed, N. (2017). chapter 9: nanodelivery systems for
nutaceuticals application. In: Nanotechnology Applications in Food, Academic Press (ed. E.O.
Alexandra and M.G. Alexandru), 179–202. Elsevier. https://doi.org/10.1016/b978-0-12-811942-
6.00009-1. ISBN 9780128119426.
https://t.me/medicina_free
Соседние файлы в папке Библиотека им академика М.И. Перельмана